Times New Roman
Total Page:16
File Type:pdf, Size:1020Kb
Master Plan 2018-2021 ciber-bbn Index 1. Introduction ……………………………………….………….…………......................................... 3 2. Executive summary................................................................................................ 8 3. CIBER-BBN at a glance ………………..…………….......................................................... 20 4. Analysis of the CIBER-BBN current situation …………………..……………………………….. 43 5. Definition of CIBER-BBN objectives and strategies............................................... 62 6. Appendix …………………………………………………………………………………………………………. 87 1. Introduction 1. Introduction 1. Introduction During the last years CIBER-BBN has been driven by the 2014-2017 Strategic Plan which came to an end in 2017. At that moment it was necessary to define the new objectives and design a new roadmap for the next 4-year period. The following pages describe the results of an in-depth analysis of CIBER-BBN situation at some point in 2017 and the outcomes of several working sessions held out by the CIBER-BBN Steering Committee along the year 2017. The purpose of this strategic document is to know the departure situation and to define a series of actions and measures allowing CIBER-BBN to achieve its goals in terms of transference, translation and scientific excellence. CIBER-BBN is wide and complex community. In order to listen to all voices of this group of people an important element in this reflection has been the conduction of a survey, which has been distributed to all researchers involved in CIBER-BBN (Heads of Group, researchers from institutions and CIBER staff). The outcomes of this survey have been taken into consideration in the definition of the measures to be implemented in the following years. It is the aim of CIBER-BBN Scientific Direction to make the most of our resources and to contribute to the position of the whole CIBER consortium in the high level of scientific excellence. Ten years after its creation, CIBER is today, with 11 thematic areas, the most important Spanish entity devoted to biomedical research, gathering nearly 430 research groups and 6.500 researchers. I would like to take this opportunity to thank all CIBER-BBN members for their constant effort and commitment with science. Ramón Martínez Máñez Scientific Director of the CIBER-BBN 4 2. Methodology for the development of the • To perform an internal REFLECTION Master Plan PROCESS in the Steering Committee’s framework in order to define the main The development of CIBER-BBN Master Plan guidelines in terms of human resources, includes the following activities: funding, research programme, transfer and • To lead a DIAGNOSIS of the current translation, organisation and management. situation evaluating the fulfilment of the • To develop a MASTER PLAN containing the management, scientific and translation main strategic areas, the specific measures objectives recommended at the previous stage. Master Plan’s metholology 1 2 3 ANALYSIS AND DIAGNOSIS STRATEGIC REFLECTION MASTER PLAN OF THE CURRENT PROCESS DEVELOPEMENT SITUATION SIX WORKSHOPS WITH THE (2018-2021) STEERING COMMITTEE W OBJECTIVES AND QUANTITATIVE analysis S SWOT O T STRATEGIES SCIENTIFIC and QUALITATIVE analysis MONITORING PLAN TRANSFER programme 34 HUMAN RESOURCES individual interviews programme 192 VISIBILITY CIBER-BBN’s Community completed surveys ECONOMIC IMPACT 5 and the monitoring indicators of the centre • Manuel Sánchez, Managing Director; for the next four years. • Begoña Pérez, Scientific Director Assistant; Thirty-four individual interviews to • Jesús Izco, Platform programme manager; stakeholders have been carried out including the Steering Committee, Scientific Advisory • Theodora Tsapikouni, Bioengineering and Board, Medical Advisory Board, principal Medical Imaging programme manager; investigators of the main research areas, • Aída Castellanos, Biomaterials and programme managers, CIBER BBN spin-off Advanced Therapies programme manager; managers, hired researchers and other leading Research Institutions‘ management. • Johanna Katharina Scheper, Nanomedicine programme manager; Besides, six strategic meetings have been hold with the Steering Committee to discuss the • Nerea Argarate, Nanomedicine programme main strategic lines of the Master Plan. manager; People interviewed in the framework of this • Fernando Santos, Industrial Transfer Master Plan are: programme manager; • Ramón Martínez, Scientific Director; • Begoña Castro, Scientific Director of Histocell; • José Becerra, Deputy Scientific Director; • Alberto A. Gabizón, PhD Professor and • Jordi Aguiló, Bioengineering and Medical Chairman, Shaare Zedek Oncology Institute Imaging coordinator; Hebrew University-School of Medicine • Julio San Román, Biomaterials and Jerusalem; Advanced Therapies coordinator; • Joan Bigorra, Head of Innovation, Hospital • María Pilar Marco, Nanomedicine Clínico de Barcelona; coordinator; • Pilar Calvo, Chief of Pharmaceutical • Jaume Veciana, ICTS / Platforms Development in PHARMAMAR; coordinator; • Anna Lluch, Head of Hematology and • Simó Schwartz, Industrial Transfer Oncology Department, Hospital Clínico coordinator; Universitario de Valencia; • Ramón Mangues, Clinical Translation • Joaquín Arenas, Scientific Director of Coordinator; Instituto de Investigación del Hospital 12 de Octubre; • Jesús Santamaría, Strategic Plan coordinator; • Jesús Jiménez, Scientific Director of CIC bioGUNE; 6 • Manuel Doblaré, principal investigator, • Begoña Castro, Scientific Director of Universidad de Zaragoza (former Scientific Histocell Director of the CIBER-BBN); Nanomedicine: • Pablo Laguna, principal investigator, • Patrick Boisseau, Business Development in Universidad de Zaragoza (former Scientific Nanomedicine at CEA-Leti, Chair of the Director of the CIBER-BBN); Executive Board of European Technology • Xavier Trepat, principal investigator, Platform on Nanomedicine, France; Instituto de Bioingeniería de Cataluña, IBEC; • Wolfgang Parak, Philipps Universität • Santiago Grijalvo, CIBER-BBN hired Marburg, Germany; researcher; • Alberto A. Gabizón, PhD Professor and • Gema Martínez, CIBER-BBN hired Chairman, Shaare Zedek Oncology Institute researcher; Hebrew University-School of Medicine Jerusalem; • Isabel García, CIBER-BBN hired researcher. Horizontal: • Santiago Sala, Nanomol Technologies Founder; • Joan Bigorra, Head of Innovation, Hospital Clínico de Barcelona; • Pedro Moreo, EBERS Founder; • Pilar Calvo, Chief of pharmaceutical Members of the Scientific Advisory Board and development in PHARMAMAR; Medical Advisory Board are: • Arcadi García, Arrhythmia Head of Unit of Bioengineering and Medical Imaging: the Cardiology Department at Hospital • Niilo Saranummi (VTT Technical Research Universitario Virgen de la Arrixaca; Centre of Finland); • Enrique Gómez, Specialist in the Area of • Leif Sörnmo, Biomedical Engineering Traumatology and Orthopedics at Hospital Department (University of Lund, Sweden) Universitario La Paz; Biomaterials and Advanced Therapies: • Mª José Martí, Neurology Department at Hospital Clínico de Barcelona; • Matthias Epple, Centre for Medical Biotechnology (Univesität Duisburg-Essen, • José M. Ruíz, Specialist in the Area of Germany) Ophthalmology of the Complejo Universitario Hospitalario de Albacete; • Abhay Pandit, Centre for Research in Medical Devices (National University of • Josep Tabernero, Onco-hematology Ireland) coordinator at Hospital Vall d ́Hebrón 7 2. Executive summary 2. Executive summary 1. Introduction After analysing the cost-benefit assessment of all the activities developed in the centre, Twelve years ago, the Carlos III Health Institute CIBER-BBN strategic plan includes a human and (ISCIII) conceived a network of biomedical economic resources restructuring proposal to research centres (CIBER), structured as a public achieve greater alignment with this new consortium dedicated to promote excellence in objective. biomedicine and health science research. Consequently, the strategic plan has focused CIBER-BBN is one of the thematic areas of the on redirecting internal resources creating consortium, specialised in bioengineering, strategic programs and its related internal calls biomaterials and nanomedicine. Throughout and restructuring the management team these years, CIBER-BBN has focused its efforts according to this new configuration. and resources on building a solid base of effective collaboration among its research Additionally, other goals have been considered groups. such as opening collaboration borders to other CIBER areas, creating an objective and Achieving effective collaboration has been the transparent policy to regulate group CIBER greatest challenge during these first continuation in CIBER-BBN, implementing new years as the research groups were scattered measures aimed at motivating young research throughout the country and on numerous talent or promoting CIBER-BBN visibility. occasions their research came from very varied disciplines. According to a recent CIBER-BBN community survey, researchers consider that being part of the centre has meant a relevant improvement in their professional career due to the multidisciplinary network achieved. This important objective has been reached as CIBER has allocated many resources and programmes to strengthen collaboration among the groups. It is time to pose another great challenge for CIBER-BBN: focus on the valorisation process to get a higher number of collaborative projects with great potential for transfer. 9 First steps of the Master Plan: 1.a. Studying CIBER-BBN main results (cost –